Race Presents Mechanism of Action Data at ESMO 2025
| Stock | Race Oncology Ltd (RAC.ASX) |
|---|---|
| Release Time | 20 Oct 2025, 8:58 a.m. |
| Price Sensitive | Yes |
Race Presents Mechanism of Action Data at ESMO 2025
- Data highlights how combining (E,E)-bisantrene with doxorubicin protects against doxorubicin-induced cardiotoxicity while enhancing anticancer activity
- This preclinical data supports Race's current Phase 1 trial of RC220 in combination with doxorubicin in advanced solid tumour patients
- (E,E)-bisantrene functions as an anthracycline cardioprotective agent via decreasing double strand DNA breaks in heart muscle cells
Race Oncology Ltd presented data on (E-E)-bisantrene (RCDS1) mechanism of action at the European Society for Medical Oncology (ESMO) Congress 2025. The poster presentation summarises the results of preclinical studies and clinical observations that explore the dual anticancer and cardioprotective benefits of (E,E)-bisantrene when combined with anthracyclines like doxorubicin. The data highlights how (E,E)-bisantrene functions as an anthracycline cardioprotective agent via the clinically proven molecular pathway of decreasing double strand DNA breaks in heart muscle cells (cardiomyocytes) by reducing the activity of Topoisomerase 2b. This molecular mechanism of action is the same as the FDA-approved cardioprotective drug, dexrazoxane. Unlike dexrazoxane, (E,E)-bisantrene additively increases the anticancer activity of anthracyclines by stabilising G4-DNA & RNA structures which leads to the silencing of the key cell growth regulator, MYC. Preclinical studies showed that co-administration of (E,E)-bisantrene with doxorubicin protects against doxorubicin-induced cardiotoxicity while enhancing overall anticancer activity through additive, non-overlapping mechanisms of action. Race's proprietary formulation of (E,E)-bisantrene, RC220, is currently being evaluated in combination with standard doses of doxorubicin (60 mg/m2) in a Phase I dose escalation trial of patients with diverse solid tumours.
Race's proprietary formulation of (E,E)-bisantrene, RC220, is currently being evaluated in combination with standard doses of doxorubicin (60 mg/m2) in a Phase I dose escalation trial of patients with diverse solid tumours.